Date Closed

December 18, 2008

Lead Office

Calgary

Value

13.00 Million USD

On December 18, 2008, Oncothyreon Inc. announced that Merck KGaA of Darmstadt, Germany has licensed the right to manufacture Stimuvax(R) and, through its affiliate EMD Serono Canada Inc., purchased current inventory and certain assets utilized for the manufacture of Stimuvax from Oncothyreon for consideration which includes net payments to Oncothyreon totalling approximately US$13 million.  In conjunction with this transaction Merck KGaA, through its affiliate EMD Serono Canada Inc., has assumed control of Oncothyreon's Edmonton, Canada, facility, which is primarily utilized for the manufacture and development of Stimuvax. In addition, Merck KGaA will be responsible for all further development costs related to Stimuvax, including commercial-scale manufacturing process development, and for the cost of goods at commercialization.

Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic products for the treatment of cancer.

Merck KGaA is a German multinational chemical, pharmaceutical and life sciences company headquartered in Darmstadt, with around 40,000 employees in around 70 countries.

McCarthy Tétrault LLP advised Merck with a team led by Andrew Grasby.